x.com· @ · X·· 2026-04-23Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
zoldonrasib and VS-7375 in G12D remain Phase 1 — strong numbers, small samples, not head-to-head.
Body
KRAS G12D mutations remain an unmet need in #NSCLC.
Phase I data for zoldonrasib:
📊 ORR 52%
📈 DCR 93%
⏳ PFS 11.1 months
🧪 Manageable toxicity (no grade 4/5 AEs)
🗣️ Presented by Jonathan W. Riess, MD (@riess_md) at #AACR26
Read more: https://t.co/xG8jO3xbhv https://t.co/88LzQbeECq
Heat 5 · 2 likes · 1 reply · 2 reposts
Source: x.com · x.com